You can buy or sell ICPT and other stocks, options, ETFs, and crypto commission-free!
Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Read More Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
BRIEF-Intercept Receives Complete Response Letter From FDA For Obeticholic Acid For The Treatment Of Fibrosis Due To Nash
June 29 (Reuters) - Intercept Pharmaceuticals Inc: * INTERCEPT RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR OBETICHOLIC ACID FOR THE TREATMENT OF FIBROSIS DU
— per share
Expected Aug 6, Pre-Market